Xvivo Perfusion AB (publ) decided on the Extraordinary General Meeting on April 10, 2017, to conduct a directed share issue to institutional investors. This issue was registered at the Swedish Companies Registration Office on April 13, 2017. Consequently, Bure Equity AB's holding in Xvivo Perfusion AB decreased from 20.7% to 18.8%.
Bure Equity AB's share of capital and votes amounts to 18.8%.
Bure Equity AB (publ)
Contact at Bure:
Henrik Blomquist, CEO
Tel. +46 (0)8 614 00 20
The information contained herein is subject to the disclosure requirements of Bure Equity AB (publ) under the Swedish Securities Market Act. The information was publicity communicated on 19 April 2017 at 9.00 a.m. CET.